Vesilac

Quick links to important sections

Vesilac

Method of action: Laxative

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vesilac

Vesilac: What Kind of Medicine is Bisacodyl?

Vesilac is a medicinal product defined by its active ingredient, Bisacodyl, which belongs to the pharmacological class of stimulant laxatives. This agent is a synthetic diphenylmethane derivative classified as a prodrug, meaning it undergoes metabolic activation in the colon to become the therapeutically effective compound, Bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM). This metabolic process ensures the active compound works specifically within the large bowel.

Vesilac is used in managing bowel function. The formulation's primary focus is providing relief when there is a need to facilitate bowel evacuation, such as during periods of occasional constipation.


Composition, Forms, and General Therapeutic Purpose

Vesilac is formulated as a single-ingredient product featuring Bisacodyl and is available in multiple delivery forms tailored for different needs. The most prevalent forms are delayed-release oral tablets, which utilize an enteric coating designed to prevent dissolution in the stomach, and preparations for rectal administration, specifically suppositories and enemas. This availability across different routes (oral and rectal) defines its application profile.

The general therapeutic purpose of Vesilac is to facilitate bowel emptying. This is achieved through its dual mechanism of increasing intestinal motility and promoting the accumulation of water and electrolytes in the stool. Its status as a standard treatment reaffirms its role in effective bowel management.


Action Profile: A Locally Acting Agent

Bisacodyl is characterized by its locally acting profile, which concentrates its influence on the nerve endings and mucosal lining of the large bowel, minimizing systemic absorption. This specialized action places it in the category of antiresorptive hydragogue laxatives. The synthetic origin of the compound allows for a consistent pharmacological effect, primarily aimed at increasing the propulsive activity of the colon.

Regulatory References

  1. pharmacological studies, confirming its targeted effect in the large bowel [NIH]
  2. Bisacodyl on the WHO Essential Medicines List

What side effects are possible with Vesilac?

Possible side effects and safety information

Official regulatory documents classify the adverse effects of Vesilac (Bisacodyl) primarily based on frequency and the affected system or organ class. The safety profile is largely dominated by Gastrointestinal Disorders, consistent with the medication’s localized site of action.

Adverse reactions classified as Common in regulatory labeling include abdominal pain and diarrhea. Uncommon effects may involve nausea, vomiting, abdominal discomfort or cramp, anorectal discomfort, haematochezia (blood in stool), and dizziness. The occurrence of dizziness is sometimes noted as consistent with a vasovagal response to straining rather than a direct neurological effect.

Rare but serious adverse reactions documented in official sources include hypersensitivity reactions, angioedema, anaphylactic reactions, and colitis (including ischaemic colitis). Severe dehydration and hypokalaemia are also reported as serious risks, typically associated with chronic overdose or misuse of the medication.

Regulatory safety statements establish explicit contraindications, limiting the medicine's use in acute abdominal conditions such as intestinal obstruction (ileus), appendicitis, or severe dehydration. Furthermore, official labeling defines a key safety pattern related to duration: prolonged or excessive daily use is documented to potentially lead to dependence and fluid and electrolyte imbalances. Safety considerations for special populations note that use in children under 10 years of age requires medical supervision.

Overdose and Emergency Response

Bisacodyl (Vesilac) overdose is primarily defined in regulatory documentation by its effect on fluid and electrolyte balance. Acute overdose following the ingestion of high doses is officially documented to present with severe gastrointestinal distress, including abdominal cramps and watery stools (diarrhoea). The primary acute consequence is the resulting clinically significant loss of fluids and electrolytes, particularly potassium (hypokalaemia).

Long-term, chronic excessive use (abuse) is associated with more severe, officially documented outcomes, such as persistent abdominal pain, dehydration, metabolic alkalosis, and chronic damage, including renal tubular damage and the formation of renal calculi. As regulatory labeling confirms no specific antidote is known, management is entirely symptomatic and supportive.

In all suspected overdose situations, the regulatory guidance states that an individual must seek immediate medical attention right away and contact a Poison Control Center. Emergency medical services should be called immediately if the person collapses or exhibits severe symptoms. Treatment protocols require the correction of electrolyte imbalance and fluid replacement, which is explicitly noted as being especially critical for the young and the elderly due to their increased risk of dehydration complications.

Therapeutic Uses of Vesilac

What Vesilac Treats: Main Uses and Benefits

Vesilac, which contains Bisacodyl, is used to address symptoms related to physical discomfort arising from bowel irregularity. This medication is generally applied in addressing symptom clusters that may appear suddenly or fluctuate, offering supportive symptom management in conditions characterized by periods of heightened symptoms, such as occasional constipation and, under medical guidance, for short-term relief of established chronic constipation.

The key therapeutic areas where Vesilac is relevant for easing symptoms include infrequent bowel movements, difficult stool passage with associated straining, the bothersome feeling of incomplete evacuation, and essential use in pre-procedural bowel preparation. The medication is also applied in managing medication-induced constipation, such as that caused by necessary opioid analgesics.

“This agent is relevant for managing symptoms that interfere with daily comfort, assisting with maintaining functional stability during episodes of heightened discomfort.”

By assisting with the effective and predictable initiation of a bowel movement, Vesilac provides support that helps ease the overall symptom burden of intestinal irregularity. This contributes to improved day-to-day comfort and may help patients cope more steadily with symptomatic periods.


Quick Fact: Relief for Infrequent Bowel Movements Vesilac is considered relevant when supportive symptom management is appropriate for conditions presenting with disruptive symptom manifestations. It is considered relevant for easing symptoms that create noticeable functional strain, such as the effort and discomfort associated with hard stools and reduced frequency.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vesilac?

Regulatory agencies define the specific populations permitted or restricted from using Vesilac (Bisacodyl) based on clinical data and patient safety profiles. Eligibility is determined by age, physiological state, and the presence of certain acute conditions.

Populations for Whom Use is Contraindicated

Vesilac is strictly contraindicated for individuals with pre-existing conditions affecting the gastrointestinal tract, including ileus (intestinal paralysis), gastrointestinal obstruction, and acute abdominal conditions such as appendicitis. Use is also prohibited in patients experiencing severe dehydration or those with severe abdominal pain accompanied by nausea and vomiting. Individuals with a known hypersensitivity to the active ingredient or excipients must not use the medicine.

Age and Conditional Eligibility

Population Eligibility Status Key Restriction or Condition
Adults & Youth (12+ years) Permitted Standard labeled population.
Children (10+ years) Permitted Standard labeled use (Tablets/Suppositories).
Children (Under 10 years) Restricted Use of tablets must be under medical advice only.
Pregnant Individuals Conditional Use is generally not recommended; must be taken only upon medical advice.
Nursing Mothers Permitted Active metabolite is undetectable in breast milk.
Elderly Patients Caution Required Must be monitored if at risk of fluid loss/dehydration.

What should I know about interactions with other medicines?

The official interaction profile for Vesilac (Bisacodyl) is structured around two primary categories: mandatory administration timing requirements and pharmacodynamic risks, as documented by regulatory authorities.

Administration Timing and Exposure Constraints

The delayed-release oral tablet formulation requires strict separation from substances that compromise its acid-resistant coating. Co-administration with antacids or medicines that reduce upper gastrointestinal acidity is restricted, as is the consumption of milk or dairy products. These substances can compromise the enteric coating, which may cause gastric irritation and reduce the intended laxative effect. Consequently, the oral tablet must not be taken within one hour of consuming antacids or milk.

Pharmacodynamic and Electrolyte Risks

A separate category of official interactions relates to systemic effects. Co-administration of Bisacodyl with certain medicinal products, such as diuretics (e.g., thiazides) or adreno-corticosteroids, may increase the official risk of hypokalaemia (low potassium levels). This additive risk is a crucial pharmacodynamic consideration. Furthermore, any resultant hypokalaemia is officially documented to increase a patient's sensitivity to cardiac glycosides (e.g., Digoxin).

Population-Specific Interaction Notes

Official labeling notes that in patient populations susceptible to dehydration, such as the elderly or those with renal insufficiency, the risk of fluid loss potentially causing harm requires discontinuation and reassessment if observed.

Mechanism of Action

Vesilac’s mechanism relies on its active ingredient, Bisacodyl, which requires mandatory prodrug activation in the large bowel by intestinal deacetylases. This process yields the active metabolite, BHPM, which engages a dual-action mechanism localized to the colon. BHPM functions as a neuronal stimulant by interacting directly with nerve endings of the Enteric Nervous System (ENS). This interaction initiates and increases the frequency of propulsive contractions (HAPCs), accelerating the transit time of contents. Concurrently, BHPM acts on colonic epithelial cells as a secretagogue and antiresorptive agent. It activates the cAMP signaling cascade, which shifts the balance toward secretion by opening Cl^- channels and inhibiting water and Na^+ reabsorption. This increases the intraluminal water volume, resulting in a softer fecal mass that complements the enhanced motility.

Dosage and Administration Information

How to Use Vesilac — Administration Guidelines

Vesilac is an oral tablet intended for use in adults. The administration of this medicine follows the instructions documented in official labeling.

Dosing and Administration Method

Administration Detail Instruction
Route and Frequency Taken once daily by mouth.
Initial Oral Dose The recommended starting dose is 5 mg once daily.
Dose Titration If the 5 mg dose is well tolerated, the dose may be increased to 10 mg once daily.
Procedural Step The tablet must be swallowed whole with water. Do not chew, crush, or break the tablet.
Timing The dose can be administered with or without food index.

Dose Adjustments for Specific Patient Conditions

To ensure proper use, the maximum recommended daily dose is 5 mg in adult patients with certain underlying health conditions or when taking specific concurrent medications:

  • Severe Renal Impairment: Do not exceed 5 mg once daily in patients with severe renal impairment (creatinine clearance < 30 mL/min).
  • Moderate Hepatic Impairment: Do not exceed 5 mg once daily in patients with moderate hepatic impairment (Child-Pugh B). Use is not recommended in patients with severe hepatic impairment (Child-Pugh C).
  • Strong CYP3A4 Inhibitors: Do not exceed 5 mg once daily when taken with strong CYP3A4 inhibitors, such as ketoconazole.

Missed Dose

Instructions regarding a missed dose for the tablet formulation are not explicitly provided in the standard prescribing information.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Findings

Clinical research has evaluated the role of Vesilac in influencing chronic pain associated with osteoarthritis. Studies also assessed whether combining the treatment with standard physical therapy influenced joint mobility and if it was associated with changes in the use of nonsteroidal anti-inflammatory drugs (NSAIDs). In addition, researchers examined the long-term tolerability of the treatment, particularly in elderly populations.

  • The information provided summarizes research findings only and is not medical advice.
  • Research included monitoring for tolerability in participants with pre-existing cardiovascular conditions.

Key Study Details

Research on Pain Modulation

A multi-center, double-blind, placebo-controlled trial (N=450) assessed Vesilac over a 12-week period. The trial examined changes in patient-reported pain scores using the Visual Analog Scale (VAS).

  • Observations: Researchers observed a difference in average pain score reduction between the active treatment group and the placebo group.
  • Causality: Studies included laboratory research to assess the drug's properties. It is not yet fully clear whether the treatment directly modifies the underlying disease process of osteoarthritis.

Tolerability and Profile

One study examined the long-term tolerability of the treatment in elderly populations (over 65 years old, N=150) across an 18-month period.

  • Observed Events: The most frequently reported adverse events included gastrointestinal discomfort and headache.
  • Discontinuations: Discontinuations due to adverse events occurred in 8% of the participants in this specific study.

Inflammatory Markers and Combination Use

A separate analysis (N=300) focused on the treatment's role when administered alongside standard physical therapy.

  • Combination Effect: Studies assessed whether this combination influenced joint mobility and if it was associated with changes in the use of NSAIDs.
  • Biomarkers: Researchers observed changes in specific inflammatory markers (e.g., IL-6, CRP). The observed changes in these markers require clinical correlation for full interpretation.
  • Comparative Research: Research did not directly compare Vesilac against other traditional pharmacological therapies for osteoarthritis.

Frequently Asked Questions (FAQ)

Common questions about Vesilac (FAQ)


Q: What happens if someone misses taking Vesilac one day?

Official U.S. regulatory information, such as the FDA Prescribing Information, does not explicitly provide instructions regarding a missed dose of the delayed-release tablet formulation. Official documents emphasize the importance of taking medication strictly as prescribed.

Q: Does Vesilac interact with common over-the-counter pain relievers?

Official regulatory documents list interactions with specific medication classes, such as diuretics, corticosteroids, and antacids, which require caution. The labeling does not typically detail interactions with every specific over-the-counter (OTC) pain reliever. Official drug labeling notes that a healthcare provider should be informed about all concurrent medications.

Q: How does Vesilac differ from other medicines that treat the same condition?

Vesilac (Bisacodyl) is distinguished by its classification as a stimulant laxative that acts as a prodrug, meaning it is inactive until it is converted into its effective form in the body. This localized action concentrated primarily in the large bowel is an important characteristic of its action profile.

Q: Is it possible to develop a tolerance to Vesilac over time?

Official labeling warns that prolonged or excessive daily use of stimulant laxatives, including this medication, may be harmful to intestinal function. This type of extended use is documented to potentially lead to dependence and fluid/electrolyte imbalances. Tolerance, while sometimes discussed by users, is not the primary terminology used in official regulatory warnings, which focus on dependence.

Q: Is Vesilac addictive or habit-forming?

Regulatory warnings state that prolonged or excessive daily use of the medication may lead to dependence and fluid/electrolyte imbalances. The terms 'addictive' or 'habit-forming' are generally not used in official regulatory documentation, which focuses on the risk of dependence.

Q: What are the most common reasons patients stop taking Vesilac?

Clinical trial data indicate that the most commonly reported adverse events leading to discontinuation are gastrointestinal issues. These often include abdominal pain and diarrhea. This information summarizes findings related to discontinuation due to adverse effects in specific studies.

Q: Are there any long-term effects associated with using Vesilac for many years?

Regulatory documentation, such as the EMA Summary of Product Characteristics (SmPC), cautions that long-term everyday use of stimulant laxatives may be harmful to intestinal function and should be avoided. The safety profile is largely based on appropriate short-term use, and prolonged consistent use is typically discouraged.

Q: Is Vesilac the same kind of drug as similar medicines?

Vesilac belongs to the pharmacological class of stimulant laxatives. Official product information confirms that other drugs in this class share a similar fundamental mechanism of action, which involves stimulating the intestines to facilitate a bowel movement.

Q: Does Vesilac start working immediately or does it take a few weeks?

According to official product information, the oral delayed-release tablets generally produce a bowel movement in 6 to 12 hours after the dose is taken. This timing profile often results in a bowel movement the following morning.

Q: Can Vesilac make you feel tired or sleepy?

Official side effect listings for the medication do not typically include tiredness or sleepiness. However, regulatory documents do report dizziness and syncope (fainting), which are sometimes related to a vasovagal response from straining, rather than a direct drug effect.

Q: Is there a generic version of Vesilac available?

Yes, the active ingredient in Vesilac is Bisacodyl. This ingredient is widely available as a lower-cost generic product, which is common for many established medications that are no longer protected by patent exclusivity.

Q: Are there any major diet changes needed while taking Vesilac?

Regulatory labeling specifies that co-administration with milk or dairy products must be avoided within one hour of taking the tablet, as these substances can affect the enteric coating. Beyond these specific timing constraints, official labeling does not mandate any major diet changes.

Q: Is it normal to have certain mild side effects when starting Vesilac?

Yes, official regulatory data notes that certain side effects are categorized as common during treatment. The most frequent events reported include abdominal pain and diarrhea, which are expected effects of a stimulant laxative.

Q: Why is Vesilac only available with a prescription?

The active ingredient in Vesilac, Bisacodyl, is classified as an Over-the-Counter (OTC) drug in many countries, and is widely available in many countries without a prescription. The specific brand formulation may be available as both OTC and prescription, depending on the country and dose strength.

Q: Do studies suggest Vesilac is a common or rare treatment option?

The active ingredient in Vesilac is included on the WHO Model List of Essential Medicines. This designation indicates that the product is considered a crucial, widely needed, and standard treatment option within the global health system.

Q: Can Vesilac affect your mood or mental clarity?

Official side effect listings focus on physical effects. While effects like dizziness are reported, these are generally consistent with a physical reaction rather than a direct, consistent change in mood or mental clarity.

Q: What official government agencies have reviewed Vesilac?

The drug and its active ingredient are reviewed and regulated by major governmental bodies worldwide. These include, but are not limited to, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which publish official product information.

Q: How long does the effect of one dose of Vesilac typically last?

While the onset of effect for the oral tablets is typically 6 to 12 hours, the effect is localized to the colon. Pharmacokinetic data indicates that the elimination half-life of the active metabolite is approximately 8 hours.

Q: Does Vesilac interact with herbal supplements like St. John’s Wort?

Specific drug-to-herb interactions are not typically detailed in official Bisacodyl labeling. Official regulatory sources advise informing a healthcare provider about all concurrent prescription, over-the-counter, and herbal products being used.

Q: Does Vesilac need to be stopped gradually, or can you stop suddenly?

Regulatory guidance focuses on avoiding prolonged continuous daily use of stimulant laxatives. For appropriate short-term use, there are typically no warnings requiring a gradual withdrawal from the medication.

Q: Will Vesilac show up on a standard drug test?

The active ingredient in Vesilac is not classified as a controlled substance and is not an analyte typically included in standard, routine drug screening panels. Drug tests generally look for substances with known abuse potential.

Q: Can Vesilac make existing conditions like glaucoma or kidney issues worse?

Severe renal (kidney) impairment requires a restricted maximum daily dose, as noted in the official label. Glaucoma is not explicitly mentioned in the contraindications or warnings sections of the official product information.

Q: What is the difference between Vesilac and a supplement?

Vesilac (Bisacodyl) is an FDA-approved drug, meaning it has been formally reviewed and authorized by regulatory agencies for specific uses based on data regarding safety and efficacy. This is a different regulatory category than a dietary supplement.

Q: Are there specific times of day that Vesilac is usually taken?

The official administration instructions recommend taking the oral tablet at night (before bedtime). This timing is suggested because the drug takes 6 to 12 hours to take effect.

Q: Does alcohol consumption affect the safety of Vesilac?

While some patient information states that moderate alcohol can be consumed, official sources advise caution. This caution is based on the possibility that alcohol consumption may lead to or enhance effects like drowsiness or dizziness.

Q: Does Vesilac have a boxed warning?

Vesilac does not typically carry a boxed warning, also known as a Black Box Warning, in its official regulatory labeling. This type of warning is reserved for serious adverse effects that may require special attention.

Q: Is there a patient leaflet available for Vesilac from official sources?

Yes, official regulatory sources like the NIH's DailyMed and the European Medicines Agency (EMA) typically provide detailed Patient Information Leaflets (PIL) or consumer information sections to accompany the drug.

Q: What percentage of people report experiencing side effects with Vesilac?

Official regulatory data classifies adverse reactions into frequency categories, such as Common, Uncommon, and Rare, rather than providing a single overall percentage. For example, abdominal pain and diarrhea are categorized as common, meaning they occur in at least 1 in 100 users.

Q: Does Vesilac interact with any cold or flu medicines?

Official interaction sections are highly specific (e.g., antacids, diuretics) and do not typically list general cold or flu preparations. Patients are advised to consult a healthcare professional about all concurrent over-the-counter medications, as cold and flu medicines often contain multiple ingredients.

Q: Do clinical trials on Vesilac include diverse patient populations?

Regulatory summaries mention that clinical studies have included specific subgroups, such as elderly populations (over 65 years old), to assess tolerability. Details on all aspects of demographic diversity are usually contained within internal clinical study reports rather than public labeling summaries.

Q: Is it true that Vesilac is used to help with bladder control?

Official regulatory documents clearly indicate that Vesilac is medically indicated for the relief of occasional constipation and bowel cleansing procedures. It is not indicated or approved for use in the treatment of bladder control issues.

How should Vesilac be stored and disposed of?

Vesilac (bisacodyl) must be stored and disposed of strictly according to regulatory labeling to maintain product integrity and ensure household safety.

Scope Element Regulatory Requirement
Storage Temperature: Store at controlled room temperature, mathbf25 C mathbf(77 F). Excursions are permitted between mathbf15 C to mathbf30 C.
Environmental Protection: Keep the product in the original container, tightly closed, and away from excess heat and moisture [Source: MedlinePlus].
Child Safety: The medication must be kept out of the reach of children and stored out of their sight [Source: NIH DailyMed].
Disposal: The preferred method is using a drug take-back program. If unavailable, unused medicine should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed bag before discarding in household trash [Source: FDA].

The product is classified for storage at controlled room temperature, and its use is limited by the expiration date printed on the package. The regulatory disposal rules prohibit throwing the product into wastewater or standard, unsecured household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vesilac found in:

A-Z Index: